



















































































































































Coeliac	disease	 is	 a	 systemic	 autoimmune	disease	 associated	with	 gastrointestinal	 and	extra-







A	 few	 recent	 studies	 have	 shown	 that	 Simtomax,	 a	 point	 of	 care	 test	 detecting	 IgA-/IgG-
deamidated	gliadin	peptide	antibodies	(IgA/IgG-DGP),	appeared	to	have	comparable	sensitivities	
to	 conventional	 serology.	 However,	 further	 studies	 are	 required	 to	 validate	 the	 diagnostic	
performance	of	Simtomax.	
	
The	null	 hypothesis	of	my	 thesis	 is	 that	 a	point	of	 care	 test	has	no	 role	 in	 the	diagnosis	 and	









































Figure	10:	ROC	curve	 for	 Simtomax	 for	predicting	persistent	 villous	 atrophy	 in	 known	coeliac	
disease	on	a	gluten	free	diet.	(Chapter	6)	
Figure	 11:	 ROC	 curve	 for	 IgA-TTG	 for	 predicting	 persistent	 villous	 atrophy	 in	 known	 coeliac	
disease	on	a	gluten	free	diet.	(Chapter	6)	































Table	 16:	 The	 number	 of	 patients	 for	 each	Marsh	 grade,	 and	 the	 number	 and	 proportion	 of	























































































































securing	 a	 stable	 food	 supply.	 Consequently,	wheat	 cultivation	 generated	antigens	 that	were	





it	 ‘koiliakos’,	 meaning	 abdominal.	 Centuries	 later	 in	 1887,	 Samuel	 Gee,	 a	 leading	 English	









clinical	 observation	 of	 wheat	 being	 the	 culprit	 of	 coeliac	 disease.	 Dicke	 recognised	 that	 the	
shortage	of	bread	towards	the	end	of	World	War	two,	the	so	called	‘winter	of	starvation’,	resulted	
in	clinical	improvement	in	children	who	were	fed	other	foods	such	as	rice	and	maize.	And	when	
bread	was	 airdropped	 in	Holland,	 the	 children	 rapidly	 deteriorated	 again.	 The	 toxic	 effect	 of	
wheat	was	supported	by	objective	measurements	of	growth	curves	and	faecal	fat	quantification	




John	 Paulley	 discovered	 the	 characteristic	 small	 bowel	 mucosal	 flattening	 in	 patients	 with	










‘classical’	 and	 ‘non	 classical’	 (10).	 Historically,	 coeliac	 disease	was	 considered	 a	 rare	 disease,	
featuring	 ‘classical’	 symptoms	 of	malabsorption	 including	 chronic	 diarrhoea,	 weight	 loss	 and	
failure	to	thrive	(11).	It	is	important	to	note	that	the	term	‘classical	coeliac	disease’	does	not	imply	
that	it	is	the	commoner	form	of	presentation.	In	fact,	since	the	1980s,	there	has	been	a	gradual	







Epidemiological	 studies	 have	 demonstrated	 that	 the	 true	 prevalence	 of	 coeliac	 disease	 is	
approximately	 1%	 in	 Western	 countries	 (1,	 5),	 with	 a	 female	 preponderance	 of	 1.5-2	 fold	
compared	to	males	(1,	3,	6).	The	incidence	of	coeliac	disease	has	been	on	the	rise,	through	the	
combination	of	the	advent	of	serological	testing,	heightened	awareness	of	coeliac	disease	and	a	
genuine	 increase	 in	 incidence.	 A	 recent	 Norwegian	 study	 found	 a	 three-fold	 increase	 in	 the	
incidence	of	biopsy	proven	coeliac	disease	in	children	from	2000	to	2010	(20).	A	similar	trend	has	
also	 been	 observed	 in	 adults	 where	 a	 Finnish	 group	 found	 the	 prevalence	 to	 have	 doubled	
between	1978-80	and	2000-01	(21).	The	authors	concluded	that	there	was	a	true	increase	in	the	
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Apart	 from	 improved	 case	detection	 from	 raised	 awareness,	 there	 are	other	 factors	 that	 are	





a	 part	 in	 the	 growing	 incidence	 of	 coeliac	 disease.	 Mounting	 evidence	 revealed	 that	 the	
prevalence	 of	 coeliac	 disease	 in	 Asia	 is	 climbing	 with	 an	 increasingly	 Westernised	 diet.	 The	
seroprevalence	of	coeliac	disease	was	found	to	be	1.6%	in	Asia	(Iran,	Turkey,	Israel	and	India)	











30%	of	 the	general	population	where	 coeliac	disease	 is	prevalent.	 Interestingly,	only	2-5%	of	
















T-helper	 1	 cells	 to	 produce	 inflammatory	 cytokines	 (31).	 Inflammatory	 cytokines	 such	 as	
interferon	 (IFN)-γ	 induce	 the	 activation	 and	 release	 of	 matrix	 metalloproteinases	 (MMP)	 by	
myofibroblasts,	resulting	in	mucosal	remodelling	and	villous	atrophy.	On	the	other	hand,	T-helper	




Gliadin	 also	 triggers	 an	 innate	 immune	 response	 involving	 an	 increased	 production	 of	 pro-
inflammatory	cytokines,	particularly	interleukin	(IL)-15.	IL-15	upregulates	the	natural-killer	group	




































tissue	 transglutaminase	 (TG2	 in	 the	 figure).	 Gliadin	 also	 stimulates	 an	 innate	 immune	 response	 involving	 an	




























for	 non-responsiveness	 is	 gluten	 exposure,	 whether	 inadvertently	 or	 not	 (42),	 due	 to	 the	
restrictiveness	 of	 a	 gluten	 free	 diet	 and	 the	 ubiquity	 of	 gluten	 in	 processed	 foods.	 Dietary	
adherence	 has	 been	 reported	 to	 be	 36%-96%,	 and	 is	 influenced	 by	 a	 variety	 of	 cognitive,	
emotional	and	socio-cultural	factors	(43,	44).	Other	causes	for	persistent	symptoms	should	be	





of	 other	 concomitant	 small	 intestinal	 conditions	 causing	 villous	 atrophy	 (e.g.	 small	 bowel	

























histological	 remission	 in	most	 type	 1	 RCD	 patients	 (54-56).	 In	 contrast,	 there	 is	 no	 effective	
treatment	 for	 type	 2	 RCD.	 The	 only	 drug	 that	 was	 shown	 to	 induce	 clinical	 and	 histological	
improvement	 with	 a	 significant	 decrease	 in	 the	 number	 of	 aberrant	 clonal	 IELs	 is	 an	
antimetabolite,	 cladribine.	Nevertheless,	 41%	of	 patients	 still	 died	 of	 EATL	 despite	 cladribine	
therapy	(57).	The	risk	of	lymphoproliferative	malignancies	such	as	EATL	has	been	shown	to	be	
increased	in	patients	with	persistent	villous	atrophy	compared	to	those	with	mucosal	healing	(HR	
2.26)	 (58).	 Fortunately,	 EATL	 is	 a	 rare	 complication	 of	 coeliac	 disease,	 as	 demonstrated	 in	 a	




The	 diagnosis	 of	 coeliac	 disease	 has	 evolved	 considerably	 over	 the	 last	 few	 decades	 as	 our	
understanding	of	its	pathophysiology	came	to	light.	According	to	the	current	British	Society	of	
Gastroenterology	 (BSG)	 (35)	and	National	 Institute	 for	Health	and	Care	Excellence	 (NICE)	 (60)	
guidelines,	a	diagnosis	of	coeliac	disease	is	made	based	on	a	positive	coeliac	serology	with	Marsh	
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Historically,	 case	 detection	 was	 an	 arduous	 three	 phase	 process	 based	 on	 the	 presence	 of	
‘classical	 symptoms’	 of	 malabsorption,	 with	 non-specific	 tests	 assessing	 for	 small	 bowel	
absorption,	such	as	faecal	fat,	and	a	confirmatory	jejunal	biopsy	showing	villous	atrophy.	Because	
there	are	other	 causes	 for	 villous	atrophy	apart	 from	coeliac	disease,	a	 relationship	between	
gluten	and	the	small	bowel	mucosa	had	to	be	demonstrated.	This	consisted	of	phase	two	showing	
symptom	resolution	on	a	gluten	free	diet	and	a	second	biopsy	showing	mucosal	healing.	A	third	



















for	 the	 diagnosis	 of	 coeliac	 disease.	 In	 1983,	 a	 Polish	 dermatologist	 Chorzelski	 discovered	



















where	 TTG	has	 a	mildly	 raised	 titre	which	may	be	 a	 false	 positive	 if	 EMA	 is	 negative),	 and	 a	
confirmatory	duodenal	biopsy	for	those	with	a	positive	EMA.	On	the	other	hand,	the	European	
Society	 for	 Paediatric	 Gastroenterology	 Hepatology	 and	 Nutrition	 (ESPGHAN)	 guidelines	
recommend	that	paediatric	patients	no	longer	require	biopsies	to	confirm	the	diagnosis	of	coeliac	
disease	if	they	have	TTG	levels	10	times	over	the	upper	limit	of	normal,	positive	EMA	and	the	





At	present,	 a	gluten	 free	diet	 for	 life	 is	 the	only	effective	and	available	 treatment	 for	 coeliac	
disease.	Small	bowel	absorption	should	be	assessed	by	testing	for	full	blood	count,	ferritin,	folate	
and	B12.	Liver	function	tests	should	also	be	performed	as	coeliac	disease	can	be	associated	with	
deranged	 liver	 enzymes.	 A	 recent	 study	 showed	 that	 liver	 function	 was	 deranged	 in	 40.6%	
patients	with	coeliac	disease	at	diagnosis,	which	normalised	in	78%	patients	1.5	years	after	gluten	
exclusion.	Those	without	any	improvement	in	liver	function	should	be	tested	for	any	co-existing	
liver	 disease	 (66).	 Calcium,	 vitamin	 D	 and	 alkaline	 phosphatase	 should	 be	 monitored	 and	
supplemented	accordingly.	 Those	with	additional	 risk	 factors	 for	osteoporosis	or	 age	over	55	
should	have	a	baseline	bone	density	scan	at	one	year	after	commencement	of	a	gluten	free	diet.	












repeat	 duodenal	 biopsy	 to	 assess	 for	mucosal	 healing.	Monitoring	 of	 complications	 includes	
haematological	 and	 biochemical	 evaluation	 for	 anaemia	 and	 nutritional	 deficiencies,	 bone	
density	 scans	 for	 osteoporosis,	 and	 vaccinations	 against	 Pneumococcus	 for	 functional	
hyposplenism	 (35).	Any	suspicion	of	 serious	complications	 such	as	RCD,	ulcerative	 jejunitis	or	
EATL	 should	 be	 urgently	 investigated	 endoscopically	 with	 small	 intestinal	 biopsies	 and	 small	






















intervals	 of	 once	 every	 3-4	 days)	 was	 safe	 and	well	 tolerated	without	 immune	 activation	 or	
serious	adverse	effects	(75).	Nexvax2	will	now	enter	phase	2	trials	to	be	studied	as	an	adjunct	to	
a	gluten-free	diet.	There	are	a	number	of	other	therapeutic	options	being	studied,	but	they	are	



















healthcare	 visits	 and	 can	 lead	 to	 a	 delay	 in	 the	 patient	 undergoing	 a	 gastroscopy	 to	 obtain	
duodenal	biopsies	for	confirmation	of	the	diagnosis	and	initiation	of	treatment.	
	
The	 advantages	 of	 point	 of	 care	 tests	 are	 manifold:	 point	 of	 care	 tests	 do	 not	 require	
venepuncture	 nor	 laboratory	 processing,	 thus	 operate	 at	 a	 relatively	 low	 cost	 compared	 to	




























































Reprinted	 from	 The	 Lancet,	 Vol	 359,	
March	16,	2002,	 Sorell	 et	al.,	One-step	
immunochromatographic	 assay	 for	
screening	 of	 coeliac	 disease,	 p945.		
Copyright	(2016),	with	permission	from	
Elsevier.	 	 Also	 Lancet	 special	 credit	 -	
"Reprinted	 from	 Vol	 359,	 March	 16,	
2002,	 Sorell	 et	 al.,	 One-step	
immunochromatographic	 assay	 for	








pipette	(top	 left),	which	 is	 then	applied	to	the	test	
device	 followed	by	 5	 drops	 of	 the	 provided	 buffer	
solution	(top	right).	(a)	Results	can	be	read	within	10	
minutes.	(b)	A	red	test	line	A	indicates	a	positive	test	
result,	 a	 red	 test	 line	 B	 indicates	 the	 presence	 of	
immunoglobulin	A	 (IgA),	 and	an	 inbuilt	 red	control	







































BiocardA	 Whole	blood	 IgA	TTG	 Yes	 Yes	 Public	and	HCP	
Stick	CD1B	 Serum	 IgA/IgG	TTG	 No	 No	 HCP	only	
Stick	CD2B	 Serum	 IgA	TTG	and	AGA	 No	 No	 HCP	only	
Simple	
CD1WB	B	
Whole	blood	 IgA/IgG/IgM	TTG	 Yes	 No	 HCP	only	
Simple	
CD2WB	B	
Whole	blood	 IgA	TTG	and	AGA	 Yes	 No	 HCP	only	
Celiac	 Quick	
TestC	
Whole	blood	 IgA/IgG/IgM	TTG	 Yes	 Yes	 HCP	only	
Celiac	 Screen	
ProfessionalD	
Whole	blood	 IgA/IgG	TTG	 Yes	 Yes	 HCP	only	
Xeliac	 Test	
ProE	






















the	 high	 coeliac	 disease	 prevalence	 of	 29.9%,	 would	 contribute	 to	 the	 apparently	 high	
sensitivities	 of	 Biocard,	 as	 false	 negatives	 would	 be	missed.	 Additionally,	 the	 sensitivity	 and	









samples	 from	 139	 patients	 with	 coeliac	 disease	 and	 103	 controls	 (83).	 The	 sensitivity	 and	
specificity	of	Biocard	were	found	to	be	93%	and	94%.	However,	we	must	take	into	account	the	
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bias,	 but	 even	 so,	 the	 sensitivity	 dropped	 to	 70.1%	 (84).	 The	 low	 sensitivity	 of	 Biocard	 was	
mirrored	in	another	prospective	case	finding	study	in	a	paediatric	population	in	India	when	the	









used	stored	whole	blood	samples	 from	the	 laboratory	 instead	of	a	 fresh	whole	blood	sample	







Other	point	of	 care	 tests	 detecting	 TTG	 such	as	Celiac	Quick	 Test,	 Stick	CD1/CD2	and	 Simple	
CD1WB/CD2WB	appeared	to	be	comparable	to	serology,	but	there	are	only	a	handful	of	studies	
























than	 IgA-TTG,	 as	 well	 as	 the	 presence	 of	 IgA.	 As	 previously	 mentioned,	 gliadin	 in	 gluten	 is	





























































secondary	 care.	 The	 sensitivities	 of	 Simtomax	were	 compared	 to	 conventional	 serology	with	


















Diagnostics,	 Rheinfelden,	 Switzerland.	 It	 detects	 both	 IgA/IgG-DGP	 antibodies,	 as	well	 as	 the	
presence	of	IgA.	The	assay	is	based	on	lateral	flow	immunochromatography	using	colloidal	gold	











































including	 at	 least	 one	 biopsy	 from	 the	 duodenal	 bulb	 and	 four	 quadrantic	 biopsies	 from	 the	
second	part	of	the	duodenum.	Each	biopsy	was	fixed	in	formalin	at	the	time	of	the	gastroscopy.	






















diet,	 positive	HLA	DQ2	or	DQ8,	 and	 other	 supporting	 information	 such	 as	 family	 history	 and	
response	 to	 a	 gluten	 free	 diet.	 Non-coeliac	 causes	 of	 seronegative	 villous	 atrophy	 were	
extensively	 investigated	 for,	 including	 giardiasis,	 tuberculosis,	Whipple’s	 disease,	 small	 bowel	







Non-coeliac	gluten	sensitivity	was	diagnosed	 in	patients	who	self-report	 symptoms	related	 to	
































































with	 symptoms	 suggestive	 of	 or	 risk	 factors	 for	 coeliac	 disease	 were	 tested	with	 Simtomax.	
Positive	 individuals	 were	 referred	 for	 a	 gastroscopy	 with	 duodenal	 biopsies	 alongside	







(500/794).	Twenty-seven	 positive	 participants	 (75%)	 underwent	 a	 gastroscopy	with	 duodenal	































































symptoms	 as	 part	 of	 their	 health.	 Clinicians	 also	 fail	 to	 recognise	 opportunities	 for	 testing,	 as	
illustrated	 by	 Sanders’	 group	 where	 patients	 had	 sought	 help	 from	 multiple	 health	 care	






















Sheffield	 (Darnall,	 Foxhill,	 Manor	 Top,	 Wicker,	 Barnsley	 Road)	 over	 a	 four-month	 period.	
Recruitment	was	achieved	in	three	ways:		
1. Customers	 at	 the	 pharmacies	 were	 approached	 by	 the	 principal	 investigator	 (PI)	 i.e.	
myself	and	I	informed	them	about	the	study.	Those	who	were	interested	were	invited	to	
a	private	consultation	room	within	the	pharmacies	to	determine	eligibility	of	participation	

















2. Customers	 obtaining	 relevant	 medications	 either	 through	 prescription	 or	 over	 the	
counter	 were	 approached	 by	 the	 pharmacists	 and	 referred	 to	 the	 PI	 for	 study	
participation.	 The	 relevant	medications	 included	 treatment	 for	 possible	 symptoms	 of	










Persistent	 unexplained	 abdominal	 or	
gastrointestinal	symptoms	
Coeliac	disease	in	first	degree	relatives		
Irritable	bowel	syndrome	 Metabolic	 bone	 disorders	 (osteomalacia/	
osteoporosis)	
Prolonged	fatigue	 Unexplained	 neurological	 symptoms	
(peripheral	neuropathy	or	ataxia)	
Unintentional	weight	loss	 Unexplained	 subfertility	 or	 recurrent	
miscarriage	


























































with	coeliac	disease	ruled	out	were	 informed	of	 their	 results	and	discharged	to	primary	care.	

























and	 registered	 with	 the	 local	 research	 and	 development	 department	 of	 Sheffield	 Teaching	
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(1.1%)	 who	 were	 approached	 already	 had	 a	 coeliac	 disease	 diagnosis	 and	 were	 therefore	
excluded.	Five	hundred	individuals	met	the	eligibility	criteria	and	agreed	to	undertake	the	point	
of	care	test,	giving	a	point	of	care	test	uptake	rate	of	63%	(500/794).	There	were	369	females	























Thirty-six	 participants	 (36/500=7.2%)	 were	 tested	 positive,	 of	 which	 27	 (75%)	 subsequently	
underwent	 further	 evaluation	 with	 conventional	 serology	 and	 a	 gastroscopy	 with	 duodenal	
























asset	 for	 supporting	 and	 relieving	 the	workload	of	 clinicians.	 Existing	models	 of	 healthcare	have	
demonstrated	 that	 specialist	 nurses	 could	 provide	 effective	 care	 for	 patients	with	 inflammatory	
bowel	disease,	 for	 instance	 (98).	The	aim	of	offering	a	point	of	 care	 test	 to	at	 risk	 individuals	at	





positive	 point	 of	 care	 test	 rate	was	 7.2%,	which	was	 similar	 to	 the	 9.4%	 positive	 rate	 from	 the	













study,	 indicating	that	the	low	yield	 in	primary	care	 is	probably	not	confined	to	our	 local	area	but	
beyond.	
	
Another	 potential	 factor	 which	may	 have	 contributed	 to	 the	 low	 detection	 rate	 is	 that	 25%	 of	











































from	 non-coeliac	 gluten	 sensitivity.	 The	 aim	 of	 this	 study	 was	 to	 assess	 and	 compare	 the	
diagnostic	performance	of	Simtomax	 to	conventional	 serology	 (IgA-TTG	and	 IgA-EMA)	 for	 the	
detection	of	coeliac	disease	in	symptomatic	patients	(group	1),	and	in	patients	who	self-reported	




anaemia	 and/or	weight	 loss	 (group	 1)	 and	 patients	with	 self-reported	 gluten	 sensitivity	with	
unknown	 coeliac	 disease	 status	 (group	 2)	 were	 prospectively	 recruited.	 All	 patients	 had	
concurrent	 Simtomax,	 IgA-TTG,	 IgA-EMA,	 total	 IgA	 levels,	 and	 a	 gastroscopy	 with	 duodenal	
biopsies.	 Five	 hundred	 patients	 completed	 acceptability	 questionnaires,	 and	 inter-observer	
variability	of	the	Simtomax	results	was	compared	among	five	clinical	staff	for	400	cases.	
	






























































the	 prevention	 of	 complications	 such	 as	 osteoporosis,	 hip	 fractures	 and	 lymphoproliferative	
malignancies.	It	has	been	shown	that	serological	testing	in	patients	with	high	risk	symptoms	in	a	
clinic	setting	yielded	3.3-4.7%	coeliac	disease	detection	(94).	Similar	 results	were	obtained	by	





by	 international	 guidelines	 (35,	 36).	 However,	 serological	 testing	 for	 coeliac	 disease	 remains	
under-utilised	(4,	118).	This	could	be	due	to	a	multitude	of	factors,	including	a	lack	of	awareness	
	 65	
of	 the	 guidelines,	 inconvenience	 and	 cost.	 A	 finger	 prick	 point	 of	 care	 test	 that	 provides	
convenience	and	 rapid	 coeliac	 antibody	 results	may	have	a	 role	 in	 improving	 case	detection,	





















Group	 2:	 patients	 presenting	 to	 secondary	 care	 with	 self-reported	 gluten	 sensitivity,	 with	
gastrointestinal	and/or	extra-gastrointestinal	symptoms	related	to	gluten	ingestion.	Those	with	



















point	 of	 care	 test,	 venepuncture,	 or	 no	 preference.	 A	 similar	 acceptability	 questionnaire	 for	








an	absence	of	a	 red	band.	There	were	 five	observers	 in	 total	 for	each	case,	consisting	of	one	
gastroenterologist	and	four	other	randomly	selected	allied	health	care	professionals	(for	example	
































































	 Simtomax		 IgA-TTG		 IgA-EMA	
Sensitivity	%	(95%	CI)	 82.9	(67.9-92.9)	 78.1	(62.4-89.4)	 70.7	(54.5-83.9)	
Specificity	%	(95%	CI)	 85.4	(83.0-87.6)	 96.3	(94.8-97.4)	 99.8	(99.3-100.0)	
PPV	%	(95%	CI)	 19.5	(16.5-23.0)	 47.1	(38.3-56.0)	 93.6	(78.2-98.3)	
NPV	%	(95%	CI)	 99.2	(98.4-99.6)	 99.0	(98.3-99.5)	 98.8	(98.0-99.2)	
Positive	likelihood	ratio	(95%	CI)	 5.7	(4.6-7.0)	 20.8	(14.5-30.0)	 339.2	(83.8-1373.2)	
Negative	likelihood	ratio	(95%	CI)	 0.2	(0.1-0.4)	 0.2	(0.1-0.4)	 0.3	(0.2-0.5)	
Accuracy	%	(95%	CI)	 85.3	(83.0-87.4)	 95.5	(94.0-96.7)	 98.6	(97.7-99.2)	
	
Table	7.	Group	1:	cross	tabulation	of	Simtomax	results	by	the	reference	standard.	
	 CD	 Not	CD	 	 CD	 Not	CD	 	 CD	 Not	CD	
Simtomax	+	 34	 140	 TTG	+	 32	 36	 EMA	+	 29	 2	


















continued	 to	do	so	at	 least	until	 the	 investigations	 took	place.	Eighteen	patients	were	 tested	
positive	for	EMA	by	their	general	practitioners.	The	vast	majority	(57/61=93.4%)	of	patients	had	
gastrointestinal	 symptoms,	 and	 10	 patients	 (10/61=16.4%)	 reported	 extra-gastrointestinal	
symptoms,	 predominantly	 neurological	 complaints	 (e.g.	 headache,	 paraesthesia,	 foggy	mind,	
ataxia,	lethargy,	tongue	tingling	and	arthralgia).		
	






Table	 8:	 The	 diagnostic	 accuracy	 of	 Simtomax,	 IgA-TTG	 and	 IgA-EMA	 in	 detecting	 coeliac	
disease	 in	 patients	who	 self-reported	 gluten	 sensitivity	 (group	 two;	 n=61,	 coeliac	 disease	
prevalence	27.9%).	
	
	 Simtomax		 IgA-TTG		 IgA-EMA	
Sensitivity	%	(95%	CI)	 100	(80.5-100)	 88.2	(63.6-98.5)	 94.1	(71.3-99.9)	
Specificity	%	(95%	CI)	 79.6	(64.7-90.2)	 93.2	(81.3-98.6)	 97.7	(88.0-99.9)	
PPV	%	(95%	CI)	 65.4	(51.3-77.2)	 83.3	(62.3-93.8)	 94.1	(69.6-99.1)	
NPV	%	(95%	CI)	 100	 91.8	(81.0-97.3)	 97.7	(86.5-99.6)	
Positive	likelihood	ratio	(95%	CI)	 4.9	(2.7-8.8)	 12.9	(4.3-39.1)	 41.4	(5.9-288.5)	
Negative	likelihood	ratio	(95%	CI)	 0		 0.1	(0-0.5)	 0.06	(0.01-0.4)	





	 CD	 Not	CD	 	 CD	 Not	CD	 	 CD	 Not	CD	
Simtomax	+	 17	 9	 TTG	+	 15	 3	 EMA	+	 16	 1	







In	 regards	 to	 patient	 acceptability,	 Simtomax	 had	 significantly	 higher	 patient	 satisfaction	
compared	 to	 venepuncture.	 The	 difference	 in	 the	 scores	 between	 the	 two	 groups	 were	







	 Simtomax	 Venepuncture	 Mann-Whitney	U	test	
Blood	collection	process:	 	 	 	
Score	for	comfort	level	of	the	test	 4.7	 3.3	 U=2988.5,	 Z=12.027,	
p<0.001,	r=0.506	
Score	for	speed	and	ease	of	the	test	 4.7	 3.3	 U=2182.5,	 Z=13.443,	
p<0.001,	r=0.566	
Convenience:	 	 	 	
Satisfaction	 score	 for	 having	 the	 test	
performed	during	the	consultation	(for	
Simtomax)	 vs	 separately	 from	 the	
consultation	by	the	phlebotomy	service	
(for	venepuncture)	
4.8	 2.9	 U=1086.5,	 Z=14.675,	
p<0.001,	r=0.617	
Quality	of	care:	 	 	 	
Satisfaction	 score	 for	 obtaining	 test	
results	 within	 10	 minutes	 (for	
Simtomax)	vs	a	few	days	to	a	week	(for	
venepuncture)	
4.8	 3.1	 U=583.5,	 Z=15.597,	
p<0.001,	r=0.656	
Satisfaction	 score	 for	 obtaining	 and	
discussing	 the	 test	 results	 with	 the	
clinician	within	 the	 same	 consultation	
(for	 Simtomax)	 vs	 at	 a	 later	 date	 (for	
venepuncture)	










Fleiss	 Kappa	 coefficient	 of	 0.895	 overall.	 Sub-analysis	 revealed	 a	 high	 level	 of	 agreement	 for	
definite	red	bands	(Kappa	0.887)	and	absence	of	red	bands	(Kappa	0.956).	The	level	of	agreement	
































Another	 strength	 of	 this	 study	 is	 that	 the	 patient	 cohort	 had	 a	 coeliac	 disease	 prevalence	
consistent	 with	 real	 life	 case	 finding	 in	 patients	 with	 high	 risk	 symptoms,	 which	 have	 been	
reported	to	be	3-4.7%	(94,	95).	A	much	higher	coeliac	disease	prevalence	is	a	common	flaw	in	













tests	 in	 the	 literature.	 Furthermore,	 the	 methodology	 of	 using	 a	 Likert	 scale	 provided	 a	
quantitative	 rather	 than	 qualitative	 measure	 of	 acceptability.	 Qualitative	 interviews	 would	
provide	 a	 more	 informative	 representation	 of	 patient	 acceptability.	 	 However,	 patient	
acceptability	was	a	secondary	outcome	and	not	the	main	focus	of	this	study.	
	
What	 is	 noteworthy	 is	 the	generally	 lower	 sensitivities	of	 IgA-TTG	and	 IgA-EMA	compared	 to	
previous	serological	studies	(126,	127).	There	are	several	potential	reasons	for	this.	Although	a	
systematic	 review	 in	2006	showed	that	 the	pooled	sensitivities	of	 IgA-TTG	and	 IgA-EMA	from	
published	data	were	93%	(range	70-100%)	and	specificities	were	>98%	(range	90-100%)	for	both,	
the	 authors	 indicated	 that	 these	 figures	were	 likely	 to	be	 falsely	 high	due	 to	methodological	
shortcomings	 in	 most	 studies	 (126).	 Firstly,	 many	 studies	 did	 not	 biopsy	 controls	 (i.e.	 take	





















All	 these	 factors	 explain	 the	huge	 variability	of	 IgA-TTG	 sensitivities	 and	why	 the	 sensitivities	








in	 the	 reported	disease	prevalence	 is	 likely	due	 to	differences	 in	 the	 study	population,	 study	
design,	 recruitment	methods	 and	 diagnostic	 criteria.	 For	 example,	 our	 disease	 prevalence	 of	
27.9%	is	higher	than	the	7%	reported	by	Aziz	et	al.	which	was	derived	from	a	UK	population-
based	questionnaire	targeting	 individuals	with	 gluten	 related	 symptoms	 (109),	 as	 opposed	 to	
symptomatic	 individuals	 actively	 presenting	 to	 primary	 care	 who	 were	 then	 referred	 on	 to	
secondary	care	for	further	evaluation.	Our	group	2	patients’	gluten	related	symptoms	may	have	
prompted	 more	 proactive	 coeliac	 screening	 by	 their	 general	 practitioners,	 thus	 possibly	

















seronegative	 coeliac	 disease	 detected	 by	 Simtomax	 alone	 whilst	 IgA-TTG	 was	 negative.	 An	
increase	in	diagnostic	yield	was	also	demonstrated	by	Hoerter	et	al.	recently,	where	the	use	of	
IgA-DGP	 serology	 resulted	 in	 a	 15%	 increase	 in	 coeliac	 disease	detection	where	 IgA-TTG	was	
negative	(138).	However,	the	specificity	and	PPV	of	Simtomax	were	inferior	to	IgA-TTG	(85.4%	vs	
96.3%	 and	 19.5%	 vs	 47.1%	 respectively),	 due	 to	 a	 higher	 rate	 of	 false	 positives.	 This	 could	

















































































































B12	 deficiency	 (141).	 One	 way	 to	 increase	 the	 detection	 of	 coeliac	 disease	 is	 by	 screening	
individuals	with	 iron	deficiency	anaemia,	which	affects	2-5%	of	 the	general	population	 in	 the	







highly	 variable,	 thus	 committing	 clinicians	 to	 take	 duodenal	 biopsies	 if	 serology	 results	 are	
unavailable	in	order	to	avoid	missing	the	diagnosis.	However,	this	is	an	expensive	way	of	case	
detection.	A	recent	Swedish	study	showed	that	routine	duodenal	biopsy	was	ineffective,	with	a	
















Firstly,	 the	 rates	 of	 adherence	 to	 the	 BSG	 guidelines	 on	 coeliac	 screening	 in	 iron	 deficiency	







Finally,	 a	 retrospective	 analysis	 was	 performed	 to	 explore	 whether	 routine	 duodenal	 biopsy	
would	yield	any	alternative	causes	for	iron	deficiency	anaemia	other	than	coeliac	disease,	in	order	







gastroscopy	 with	 duodenal	 biopsy	 at	 four	 UK	 hospitals	 (Addenbrooke’s,	 Bradford,	 Hull	 and	
Figure	9:	A	 flow	diagram	of	how	a	point	of	 care	 test	 in	endoscopy	would	 fit	 in	within	 the	
endoscopy	setting.		
	
Starting	 from	 the	 top	 second	 left	 picture	 in	 a	 clockwise	 fashion:	 The	 patient	 enters	 the	
endoscopy	 unit,	 undertakes	 a	 Simtomax	 test	 performed	by	 a	 healthcare	 professional	 if	 iron	
deficiency	anaemia	is	present.	If	the	patient	has	a	positive	Simtomax,	the	endoscopist	would	






Whipps	Cross)	over	a	12	month	period	 ranging	 from	2012	 to	2014.	The	availability	of	 coeliac	
serology	prior	to	gastroscopy	was	reviewed.		
	
Group	 2	 was	 a	 prospective	 study	 comparing	 the	 sensitivities	 of	 Simtomax	 to	 conventional	
serology	in	an	iron	deficient	cohort.	Patients	with	iron	deficiency	with	or	without	anaemia	were	
prospectively	 recruited.	 These	 patients	 attended	 for	 a	 gastroscopy	 at	 the	 Royal	 Hallamshire	
Hospital	 between	 2013	 and	 2015.	 All	 recruited	 patients	 were	 consented	 for	 the	 study,	 and	






















The	primary	outcome	was	 to	assess	 the	diagnostic	accuracy	of	Simtomax	 in	detecting	coeliac	
disease	in	patients	with	anaemia.		
	


















As	 the	 PPV	 and	 NPV	 of	 a	 test	 are	 influenced	 by	 the	 pre-test	 probability,	 positive	 (PLR)	 and	




The	 group	 2	 study	 protocol	 was	 approved	 by	 the	 Yorkshire	 and	 the	 Humber	 Research	 Ethics	












































































patients	 underwent	 a	 gastroscopy,	 and	 153	 of	 those	 had	 a	 duodenal	 biopsy.	 The	 duodenal	
histology	samples	of	these	153	patients	were	analysed.	Two	patients	had	Marsh	grade	3	villous	
atrophy	on	histology-	one	had	a	positive	coeliac	serology	and	hence	was	diagnosed	with	coeliac	






	 Sensitivity	%	(95%	CI)	 Specificity	%	(95%	CI)	 PPV	%	(95%	CI)	 NPV	%	(95%	CI)	
Simtomax										100	(86.8-100.0)	 82.2	(73.7-89.0)	 57.8	(42.2-72.3)	 100	(95.9-100.0)	
IgA-TTG	 96.2	(80.4-99.9)	 91.5	(84.5-96.4)	 73.5	(55.6-87.1)	 99.0	(94.5-100.0)	













duodenosis	 such	 as	 aspirin,	 proton	 pump	 inhibitors,	 olmesartan,	 non-steroidal	 anti-
inflammatories	and	chemotherapy;	autoimmune	associations	such	as	type	1	diabetes	and	thyroid	
disorders;	and	infections	such	as	Helicobacter	pylori,	Whipple’s,	Giardia	etc.	Six	of	these	patients	
had	 a	 cause	 for	 or	 association	 with	 lymphocytic	 duodenosis:	 vitiligo,	 autoimmune	
hypothyroidism,	multiple	sclerosis,	aspirin	use,	proton	pump	inhibitor	use	and	Helicobacter	pylori	



































£4908	 (£7568-£2660)	 for	 the	 gastroenterology	 department.	 This	 equates	 to	 a	 potential	 cost	
saving	 of	 £3690	 per	 100	 gastroscopies.	 At	 a	 national	 level,	 the	 difference	 in	 the	 HRG	 tariff	
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disease	 in	 iron	deficient	patients.	The	PLR	and	NLR	were	5.63	and	0	respectively,	 indicating	a	
negative	Simtomax	test	effectively	ruled	out	coeliac	disease	in	iron	deficient	patients.		
	
The	 group	 3	 duodenal	 histology	 analysis	 revealed	 no	 alternative	 causes	 for	 iron	 deficiency	















The	 strength	 of	 the	 prospective	 study	 (group	 2)	 is	 that	 the	 sensitivities	 of	 Simtomax	 were	
measured	 against	 duodenal	 histology	 rather	 than	 serology	 as	 the	 reference	 standard.	
Furthermore,	 in	 order	 to	 reduce	 selection	 bias,	 all	 patients	 underwent	 duodenal	 biopsies	
irrespective	of	their	serology	or	Simtomax	results.	This	sets	the	study	apart	from	the	three	out	of	
four	 published	 Simtomax	 studies	 (88-90),	 where	 only	 patients	 with	 a	 positive	 serology	 or	




One	of	 the	 limitations	of	 the	study	 is	 the	 relatively	high	pre-test	probability	 in	group	2	being	
investigated	at	our	tertiary	referral	centre	for	coeliac	disease,	giving	a	coeliac	disease	prevalence	
of	19.5%.	This	referral	bias	may	falsely	increase	the	PPV	of	Simtomax,	although	the	weight	of	its	




Another	 limitation	 is	 that	even	though	the	non-specialist	group	3	cohort	represented	real	 life	
data	where	no	other	causes	 for	anaemia	apart	 from	coeliac	disease	were	 found	on	duodenal	
histology,	it	is	a	relatively	small	cohort	and	may	not	be	representative	of	other	populations.	For	
instance,	 infective	 causes	 may	 be	 seen	 in	 other	 cohorts,	 and	 their	 prevalence	 varies	 from	
different	populations	and	geographical	regions.	Two	Turkish	studies	reported	a	2%	prevalence	of	
Giardiasis	found	on	duodenal	biopsies	in	their	cohorts	with	iron	deficiency	anaemia	(151,	152).	
In	 contrast,	 a	German	 study	only	 found	a	0.2%	prevalence	of	Giardiasis	 on	 routine	duodenal	
biopsy	in	1000	unselected	patients	attending	for	a	gastroscopy	(153),	and	a	study	from	America	

































This	 is	 the	 first	 study	 that	 demonstrated	 excellent	 diagnostic	 accuracy	 of	 Simtomax	 in	 iron	
deficiency,	which	was	comparable	to	conventional	serological	 testing.	With	a	100%	sensitivity	
and	 NPV,	 Simtomax	 could	 be	 used	 judiciously	 by	 clinicians	 as	 an	 effective	 and	 cost	 saving	










































and	 the	 adherence	 score	 in	 detecting	 villous	 atrophy	 were	 67.1%,	 44.7%,	 37.7%	 and	 24.7%	




Conclusion:	 The	 sensitivity	 of	 Simtomax	 was	 higher	 than	 the	 other	 surrogate	 markers	 in	






















A	 gluten	 free	 diet	 remains	 the	 only	 treatment	 for	 coeliac	 disease	 at	 present.	 Strict	 dietary	
adherence	is	often	challenging	given	the	ubiquity	of	gluten	in	Westernised	diets	and	processed	
foods,	with	 adherence	 rates	 reported	 to	 vary	 between	 42%	 and	 91%	 (43,	 161,	 162).	 Dietary	
transgression	is	the	commonest	cause	for	non-responsive	coeliac	disease	(42,	46,	163),	which	can	


























non-invasive	 surrogate	markers	 have	 been	 shown	 to	 correlate	 poorly	 with	 persistent	 villous	
atrophy.	It	is	well	established	that	serology	is	inadequate	in	detecting	ongoing	villous	atrophy,	
with	sensitivities	of	IgA-TTG	and	IgA-EMA	reported	to	be	41-52%	and	26-31%	respectively	(166,	






is	 needed.	 A	 dietary	 assessment	 questionnaire	 was	 devised	 by	 Biagi	 and	 colleagues,	 which	
contains	four	simple	questions	based	on	the	patients’	strategy	for	gluten	avoidance	rather	than	







Quick	Test	and	Stick	CD1	and	2)	 reported	 to	be	58-100%	 (82,	84,	87-89,	121,	123,	125,	184).	
Conversely,	 there	 is	 a	 paucity	 of	 data	 examining	 the	 role	 of	 point	 of	 care	 tests	 in	 disease	
monitoring.	Previous	studies	showed	the	sensitivities	were	found	to	be	78.9%	for	Simtomax	(89),	
and	77.8%	(using	whole	blood)	and	93.5%	(using	serum)	for	Celiac	Quick	Test	in	measuring	dietary	







To	 evaluate	 the	 diagnostic	 performance	 of	 Simtomax,	 IgA-TTG,	 IgA-EMA	 and	 the	 adherence	








for	 histological	 remission	were	 prospectively	 recruited.	 All	 patients	were	 concurrently	 tested	
with	 Simtomax,	 IgA-TTG,	 IgA-EMA,	 total	 IgA	 levels.	 A	 health	 questionnaire	 regarding	 their	
symptoms	 (appendix	 9)	 and	 a	 dietary	 adherence	 questionnaire	 devised	 by	 Biagi	 et	 al.	 (183)	





diet	 or	 those	with	 raised	 serological	 titres	were	 recruited.	 Patients	who	were	 asymptomatic,	






















and	 registered	 with	 the	 local	 research	 and	 development	 department	 of	 Sheffield	 Teaching	
Hospital	NHS	Foundation	Trust	under	the	registration	number	STH15416.	Written	consent	was	























from	2013-2017	 (70%	 female,	 age	 range	16-83,	median	age	53).	 The	median	duration	of	 the	
gluten	 free	 diet	 was	 six	 years	 (76.5	 months;	 range:	 6-900	 months).	 Patient	 characteristics	
including	their	gender,	race,	median	duration	of	gluten	free	diet	in	the	villous	atrophy	group	and	












82	 n/a	 128	 n/a	 n/a	
Male	 24	 29.3	 41	 32.0	 0.6726	
Race:	Caucasian	 76	 92.7	 120	 93.8	 0.7623	
Race:	Asian	 4	 4.9	 8	 6.3	 0.6760	








Normal	bowel	habit	 42	 51.2	 71	 55.5	 0.5468	
Constipation	 12	 14.6	 20	 15.6	 0.8455	




12	 14.6	 22	 17.2	 0.7389	
Nocturnal	diarrhea	 7	 8.5	 11	 8.6	 0.9885	
Urgency	 16	 19.5	 30	 23.4	 0.5022	
Steatorrhea	 20	 24.4	 31	 24.2	 0.9774	
Bloating	 37	 45.1	 69	 53.9	 0.2142	
Weight	loss	 21	 25.6	 22	 17.2	 0.1401	
Energy	 level:	
normal	
29	 35.4	 43	 33.6	 0.7918	












where	 Simtomax	 had	 a	 significantly	 higher	 sensitivity	 than	 IgA-TTG	 (Simtomax	 vs	 IgA-TTG	
Surrogate	markers	 correctly	 testing	
negative	for	villous	atrophy.	















































































































Simtomax	 67.1	(56.0-76.9)	 59.1	(50.2-67.6)	 51.4	(45.0-57.6)	 73.6	(66.6-79.6)	 n/a	
IgA-TTG	 44.7	(33.9-55.9)	 86.4	(79.3-91.7)	 67.9	(56.4-77.5)	 70.8	(66.5-74.8)	 0.0005	
IgA-EMA	 37.7	(27.4-48.8)	 89.4	(82.9-94.1)	 69.6	(56.5-80.1)	 69.0	(65.1-72.6)	 <0.0001	
Adherence	
score	
24.7	(16.0-35.3)	 86.4	(79.3-91.7)	 53.9	(39.8-67.3)	 64.0	(60.8-67.2)	 <0.0001	
	
Table	18:	The	diagnostic	performance	of	Simtomax	in	combination	with	IgA-TTG,	IgA-EMA	and	the	




		 Sensitivity	%	(CI)	 Specificity	%	(CI)	 PPV	%	(CI)	 NPV	%	(CI)	
Simtomax	+	IgA-TTG	 71.8	(61.0-81.0)	 55.5	(46.4-64.0)	 50.8	(45.1-56.6)	 75.3	(67.7-81.5)	
Simtomax	+	IgA-EMA	 71.8	(61.0-81.0)	 56.1	(47.2-64.7)	 51.3	(45.4-57.1)	 75.5	(68.0-81.7)	
Simtomax+	
adherence	score	









































































































































This	 is	 currently	 the	 largest	 study	 evaluating	 Simtomax	 in	 disease	 monitoring,	 showing	 that	
Simtomax	 had	 a	 higher	 sensitivity	 than	 conventional	 serology	 and	 the	 adherence	 score	 in	
detecting	ongoing	villous	atrophy.		
	
One	 of	 the	 strengths	 of	 this	 study	 is	 that	 duodenal	 biopsies	 were	 taken	 from	 all	 patients	
irrespective	of	 their	 coeliac	antibody	or	adherence	 score	 results,	 ensuring	 that	 false	negative	
cases	 would	 be	 taken	 into	 account	 when	 calculating	 the	 sensitivities	 and	 specificities	 of	 the	
surrogate	markers.	The	only	other	published	study	investigating	the	role	of	Simtomax	in	disease	
monitoring	was	performed	by	Benkebil	et	al.	(89).	The	authors	tested	Simtomax	and	IgA-TTG	in	







showed	 that	 IgG-DGP	 was	 an	 effective	 surrogate	 marker	 for	 histological	 recovery,	 with	 a	
sensitivity	and	specificity	of	87%	and	89%	(at	a	positive	threshold	of	12U/ml),	versus	33%	and	
100%	 for	 IgA-TTG	 (at	 a	 positive	 threshold	 of	 5U/ml)	when	 tested	 in	 60	 patients	with	 known	
coeliac	disease	who	were	strictly	adherent,	of	which	15	(20%)	had	persistent	villous	atrophy.	ROC	
curve	analysis	 showed	 that	 IgG-DGP	substantially	outperformed	 IgA-TTG	with	an	AUC	of	0.94	
	 115	
versus	0.61	(186).	Similar	results	were	replicated	by	de	Chaisemartin’s	group	subsequently,	with	




laboratory	 IgG-DGP	 serology	 as	 previously	 reported	 (186,	 188).	 It	 is	 conceivable	 that	 the	





mentioned,	DGP	assays	are	not	widely	available	 in	 the	UK,	and	 is	not	available	 in	our	centre.	
Therefore,	DGP	assays	were	not	performed,	which	is	a	limitation	of	this	study.		
	
Another	 limitation	of	 this	 study	 is	 the	 study	 cohort-	 the	 recruited	patients	were	 referred	 for	
























provide	 instant	 DGP	 results	 during	 a	 follow	 up	 consultation,	 not	 only	 for	 the	 benefit	 of	 the	
clinicians,	but	also	as	an	immediate	feedback	for	the	patients	which	they	highly	value.	With	the	

















consistent	 with	 our	 results	 of	 24.7%	 and	 86.4%,	 however	 the	 PPV	 and	 NPV	 were	 strikingly	
different	from	our	findings.	This	could	be	due	to	the	significantly	lower	prevalence	of	persistent	




























of	 care	 test,	 Simtomax,	 had	 a	 superior	 sensitivity	 in	 detecting	 persistent	 villous	 atrophy	 in	
patients	with	known	coeliac	disease,	compared	to	the	adherence	score	and	conventional	coeliac	
	 119	
serology	 (IgA-TTG	 and	 IgA-EMA)	which	 are	 routinely	 used	 for	 disease	monitoring	 at	 present.	
Simtomax	 could	 help	 streamline	 the	 follow	 up	 process	 by	 providing	 DGP	 results	 during	 the	



















































similar	 Simtomax	 positive	 rate,	 indicating	 that	 the	 low	 yield	 in	 primary	 care	 is	 probably	 not	
confined	to	our	local	area	but	beyond.	Disappointingly,	the	limitation	of	Simtomax	lies	in	its	low	
specificity.	On	balance,	the	high	false	positive	rate	outweighs	the	advantage	of	providing	rapid	
and	 sensitive	 antibody	 results	 in	 real	 time,	 due	 to	 the	 high	 number	 patients	 who	would	 be	
















PPV	of	 Simtomax	 from	 chapter	 4	 are	 substantially	 lower	 than	 the	published	data.	Diagnostic	
performance	 is	considerably	 influenced	by	a	wide	range	of	factors.	Methodological	disparities	
such	 as	 study	 design,	 inclusion	 criteria,	 disease	 prevalence,	 reference	 standard	 and	 disease	
spectrum	 (severity	 of	 villous	 atrophy)	 are	 well	 known	 to	 affect	 diagnostic	 performance.	









may	 cause	a	 low	degree	of	haemolysis	which	would	adversely	 affect	 the	plasma	 flow	due	 to	
increased	turbidity,	and	thereby	increasing	background	noise,	hence	affecting	precision	of	the	
test.	 Moreover,	 it	 is	 also	 conceivable	 that	 the	 wicking	 rate	 and	 adsorption	 control	 of	 the	
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nitrocellulose	 membrane	 of	 the	 device	 where	 the	 assay	 binding	 occurs	 may	 play	 a	 part	 in	
influencing	sensitivities.		
	








point	 of	 care	 tests	 for	 INR	 which	 has	 been	 well	 established	 in	 its	 role	 in	 both	 primary	 and	
secondary	care	in	the	last	decade.	The	successful	implementation	of	INR	point	of	care	testing	by	
healthcare	 professionals	 was	 based	 on	 acceptable	 diagnostic	 performance	 compared	 to	
laboratory	INR	testing.	A	systematic	review	in	2012	analysing	20	studies	found	the	correlation	
coefficient	of	CoaguCheck	XS	varied	from	0.81	to	0.98,	whilst	that	of	INRatio	and	ProTime	varied	
between	 0.73	 and	 0.95	 when	 compared	 to	 laboratory	 INR	 as	 the	 reference	 standard	 (196).	
However,	uncertain	cost	effectiveness	based	on	conflicting	results	from	previous	studies	(136)	
meant	 that	 INR	point	of	 care	 testing	has	not	been	approved	 for	 routine	patient	use	 for	 self-
















Finances	 and	 time	 pressures	 also	 play	 a	 negative	 role	 from	 the	 endoscopy	 directorate’s	
perspective.	Using	Simtomax	in	endoscopy	involves	training	nurses	to	perform	the	test.	Nurses	
may	be	reluctant	to	take	it	on	as	it	consumes	more	time	and	effort	during	the	pre-assessment	













Moreover,	 the	 endoscopists	 may	 disregard	 the	 Simtomax	 test	 results,	 whether	 it	 be	 due	 to	
clinical	reasons,	hesitance	in	relying	on	the	accuracy	of	Simtomax,	or	inertia	to	change	practice,	
and	hence	the	cost	saving	potential	in	reality	may	differ	from	the	estimated	calculations	I	made.	
On	 the	 other	 hand,	 from	 the	 histopathology	 department’s	 standpoint,	 even	 though	 biopsy	
avoidance	would	 reduce	 their	workload,	 they	may	 see	 this	as	a	 reduction	of	 revenue	 for	 the	
department.	 The	 histopathology	 department	 is	 funded	 on	 units	 of	 work	 irrespective	 of	 the	
complexity	of	the	work.	Controversially,	looking	at	it	from	a	human	factor	or	work	intensity	angle,	






sensitivity	 to	 TTG	 serology,	 convenience,	 rapid	 result	 availability	 and	 high	 user	 satisfaction.	
Unfortunately,	its	low	specificity	presents	a	major	setback	and	needs	to	be	addressed.	A	recent	

























































































































































































































































































































































































































































































































































































































































Only	 positive	 POCT	 or	












































Greece	 1136	 Paediatric	 0.65%	 No	data		 No	data		
Only	 those	with	positive	





































Italy	 3559	 Paediatric	 0.50%	





Slovenia	 1480	 Paediatric	 0.47%	





Turkey	 785	 Paediatric	 0.13%	









2015	 UK	 55	 Adults	 65.40%	 72.2%	 No	data	
Sensitivities	 compared		












Lopez	2004	 Spain	 286	 Paediatric	 53.5%	 97.1%	 99%	 High	pre-test	probability.	
Stick	CD2	
(205)	Ferre-










































































































2015	 UK	 55	 Adults	 65.40%	 77.8%	 no	data	
Sensitivities	 compared	




































































2017	 Spain	 100	 Paediatric	 48%	 95.8%	 98.1%	
High	 prevalence.	
Reference	 standard	 for	







































































































































































































































The	 Point	 of	 Care	 Test,	 Simtomax,	 detects	 coeliac	 disease	 associated	 IgA	 and	 IgG	 antibodies	
against	a	unique	combination	of	deamidated	gliadin	peptides	(DGP)	as	well	as	the	total	level	of	
IgA.	 This	 ensures	 results	 are	 not	 influenced	 by	 patients	 with	 IgA	 deficiency,	 which	 is	 more	





the	 Royal	 Hallamshire	 Hospital,	 to	 obtain	 duodenal	 biopsies	 for	 histological	 confirmation	 of	
coeliac	disease.			
	















































	 	 	 	 	 	 	 	 	 	 	 	 	
Name	of	Participant	 	 	 Date	 	 	 	 Signature	
	
	 	 	 	 	 	 	 	 	 	 	 	 	















Disagree	 Neither	 Agree	 Strongly	
agree	
1. Blood	collection	process:	 	 	 	 	 	
a. The	finger	prick	was	not	painful.	 	 	 	 	 	
b. The	finger	prick	was	quick	and	easy.	 	 	 	 	 	
2. Convenience:	 	 	 	 	 	
a. I	 am	 satisfied	 that	 I	 can	 have	 the	 test	
done	 within	 the	 same	 consultation	
which	saves	me	from	having	to	make	a	
separate	 trip	 to	 the	 GP	 surgery	 or	
hospital	to	have	my	blood	taken.	
	 	 	 	 	
b. I	find	it	helpful	to	know	the	results	within	
10	minutes	so	it	saves	me	from	having	to	
travel	 for	 a	 second	 consultation	 to	
obtain	the	results.	
	 	 	 	 	
3. Quality	of	care:	 	 	 	 	 	
a. I	 am	 satisfied	 that	 the	 test	 results	 are	
available	 immediately	 rather	 than	
having	to	wait	for	a	few	days	or	weeks.	




	 	 	 	 	
4. Preference:	 	 	 	 	 	
I	prefer	a	finger	prick	test	to	a	standard	blood	
test	taken	from	a	vein.	












Disagree	 Neither	 Agree	 Strongly	
agree	
1. Blood	collection	process:	 	 	 	 	 	
a. The	blood	test	was	not	painful.	 	 	 	 	 	
b. The	blood	test	was	quick	and	easy.	 	 	 	 	 	
2. Convenience:	 	 	 	 	 	
a. I	 don’t	 mind	 having	 to	 wait	 in	 line	 to	
have	my	blood	taken	in	the	phlebotomy	
department	after	seeing	the	doctor.	
	 	 	 	 	
b. I	 don’t	 mind	 having	 to	 travel	 for	 a	
second	 consultation	 to	 obtain	 the	
results.	
	 	 	 	 	
3. Quality	of	care:	 	 	 	 	 	
a. I	 am	 satisfied	 that	 the	 test	 results	 are	
available	 within	 a	 few	 days	 to	 a	 few	
weeks.	




	 	 	 	 	
4. Preference:	 	 	 	 	 	
I	prefer	a	standard	blood	test	taken	from	a	
vein	to	a	finger	prick	test.		


















Coeliac	disease	 is	an	autoimmune	condition	 in	which	 the	body	attacks	 the	 lining	of	 the	small	












































on	 and	 password	 identification	 in	 keeping	 with	 standard	 Trust	 confidentiality	 practices.	









It	 is	 intended	to	publish	the	results	of	 the	research	 in	peer	reviewed	 journals,	and	to	present	




































responsible	 individuals	 from	 Sheffield	 Teaching	 Hospitals	 NHS	 Trust,	 or	 from	 regulatory	












































Once	per	day	 	 Twice	per	day	 											More	than	twice	per	day		
	
5.	Do	you	currently	have	any	of	these	symptoms?	
	 Flatulence	 	 	 Bloating			 				 Floating	stools				
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